Efficacy study of interferon alpha-2b on Diamond-Blackfan Anemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038510

Enrollment

Unknown

Registered

2020-09-23

Start date

2020-09-21

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diamond-Blackfan Anemia

Interventions

Case series:Subcutaneous injection of recombinant human interferon alpha - 2B

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. According to the diagnostic criteria of DBA, it conforms to the diagnosis of typical or non-typical DBA; 2. Patients with transfusion dependence who failed regular glucocorticoid treatment (transfusion dependence was defined as requiring at least 2 units or 30 ml/kg of red blood cell suspension every 8 weeks before inclusion to maintain hemoglobin >=80g/L.); 3. No conditions or intention of hematopoietic stem cell transplantation within 3 months; 4. Informed consent of the guardian and voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Children under 1 year old; 2. There are contraindications for the application of recombinant interferon -2B; 3. The guardian does not agree or cannot obtain the guardian's consent.

Design outcomes

Primary

Measure	Time frame
blood routine examination;Absolute value of reticulocyte;	—

Countries

China

Contacts

Public ContactZhu Xiaofan

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

xfzhu@ihcams.ac.cn+86 13752090418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026